Immatics N.v. · NASDAQ:IMTX
Immatics — Investor Presentation (September 2024)
72 slides from Immatics's investor presentation, Sep 16, 2024
Slide 1: Immatics Corporate Presentation
Delivering the Power of T cells to Cancer Patients © Immatics. Not for further reproduction or distribution. Immatics Corporate Presentation September 16, 2024
Slide 2: Forward-Looking Statement
Forward - Looking Statement This presentation (“Presentation”) is provided by Immatics N . V . (“Immatics” or the “Company”) for informational purposes only . The information contained herein does not purport to be all - inclusive and none of Immatics, any of its affiliates, any of its or their resp
Slide 3: Building a Leading TCR Therapeutics Company
Therapeutic O pp o rtun i t y Potential for addressing large patient populations with high prevalence targets in solid tumors Two Clinical - Stage Modalities Pipeline of TCR - T and TCR Bispecific product candidates in clinical & preclinical development Building a Leading TCR Therapeutics Company 3
Slide 4: Upcoming 2024 Catalysts for ACTengine and TCER Clinical Lead Assets
Upcoming 2024 Catalysts for ACTengine® and TCER® Clinical Lead Assets Projected Cash Runway into 2027 to Reach Multiple Value Inflections Points 4 • Targeted randomized Phase 2/3 trial 1 for ACTengine® IMA203 in 2L+ melanoma in 2024 • Next IMA203 updated at SMR Conference on Oct 11, 2024; next IMA20
Slide 5: Two Distinct TCR-based Therapeutic Modalities in Clinical Development
Two Distinct TCR - based Therapeutic Modalities in Clinical Development 5 Differentiated positioning of ACTengine® vs. TCER® based on patient population and medical need I n t r o 1 Interim data update from the ACTengine® IMA203 (published May 14, 2024) and IMA203CD8 monotherapies (published Novembe
Slide 6: Our Pipeline of TCR-based Adoptive Cell Therapies and Bispecifics
Our Pipeline of TCR - based Adoptive Cell Therapies and Bispecifics 6 I n t r o 1 Phase 1a: Dose escalation, Phase 1b: Dose expansion; 2 Immatics’ proprietary ACTallo® platform utilizing Editas’ CRISPR gene editing technology; 3 mRNA - enabled in vivo expressed TCER® molecules Phase 3 Phase 2 Phase
Slide 7: Realizing the Full Multi-Cancer Opportunity of PRAME
Realizing the Full Multi - Cancer Opportunity of PRAME ACTengine® IMA203 (TCR - T) and TCER® IMA402 (TCR Bispecific) 7 A C T eng i ne® IMA203 (TCR - T) Cancer Cell Death PRAME is one of the most promising and most prevalent, clinically validated solid tumor targets known to date Leverage the full po
Slide 8: First-in-human Data of IMA401 TCER Targeting MAGEA4/8
First - in - human Data of IMA401 TCER® Targeting MAGEA4/8 Presentation at ESMO on September 16, 2024 • Tolerability : Most common treatment - related AEs are low - grade CRS, transient lymphopenia and neutropenia • Pharmacokinetics : Median terminal half - life of 16.9 days supporting potential fur
Slide 9: ACTengine IMA203 – TCR-T Targeting PRAME
ACTengine® IMA203 – TCR - T Targeting PRAME 9
Slide 10: The Multi-Cancer Opportunity of PRAME
The Multi - Cancer Opportunity of PRAME One of the Most Promising Solid Tumor Targets for TCR - based Therapies Known To Date 10 High prevalence High target density Homogeneous expression “Clean” expression profile Clinical proof - of - concept s q N S C L C Ovarian Cancer PRAME fulfills all propert
Slide 11: ACTengine IMA203 Targeting PRAME – Mechanism of Action
ACTengine® IMA203 Targeting PRAME – Mechanism of Action Immatics’ Leading TCR - T Approach 11 I M A 203 LEUKAPHARESIS
Slide 12: ACTengine IMA203 TCR-T Product Manufacturing
ACTengine® IMA203 TCR - T Product Manufacturing Differentiated Manufacturing Process and Setup 1 - week manufacturing process followed by 1 - week QC release testing High manufacturing success rate of >95% to reach IMA203 target dose* Lean and cost - efficient process Proprietary Manufacturing Proce
Slide 13: ACTengine IMA203/IMA203CD8 TCR-T Monotherapy – Patient Flow
ACTengine® IMA203/IMA203CD8 TCR - T Monotherapy – Patient Flow 13 HLA - A*02 Testing Blood sample; Central lab Treatment & Observation Phase Long Term Follow - up Screening & Manufacturing Phase Manufacturing by Immatics Infusion of ACTengine® IMA203 TCR - T Product Lymphodepletion * Low dose IL - 2
Slide 14: ACTengine IMA203 TCR-T Trial in Advanced Solid Tumors
Data cut - off Apr 25, 2024 14 ACTengine® IMA203 TCR - T Trial in Advanced Solid Tumors Heavily Pretreated Patient Population I M A 203 Phase 1a Dose Escalation Dose Level 1 - 4 (total Safety Pop. N=28 1 ) Total Safety Population (N=65 1,2 ) Phase 1b Dose Expansion Dose Level 4/5 (total Safety Pop.
Slide 15: IMA203 Adverse Events (table continued)
table continued… 3.1 2 Nervous system disorders 1.5 1 Headache 1.5 1 Posterior reversible encephalopathy syndrome 1.5 1 Endocrine disorders 1.5 1 Inappropriate antidiuretic hormone secretion 1.5 1 Hepatobiliary disorders 1.5 1 Cholangitis 1.5 1 Immune system disorders 1.5 1 Haemophagocytic lymphohis
Slide 16: Best Overall Response for IMA203
Best Overall Response for IMA203 Objective Responses in Heavily Pretreated Melanoma Patients at RP2D Data cut - off Apr 25, 2024 16 I M A 203 55% (16/29) c O RR 13.5 months median DOR 1.2+, 21.5+ months min, max DOR 11/16 confirmed responses ongoing 67% (20/30) O R R 87% (26/30) Tumor shrinkage* 90%
Slide 17: Response over Time of IMA203
Response over Time of IMA203 Durable Responses 20+ Months after Treatment in Heavily Pretreated Melanoma Patients at RP2D Data cut - off Apr 25, 2024 17 I M A 203 Ongoing Scans at approximately week 6, month 3 and then every 3 months 55% (16/29) c O RR 13.5 months median DOR 1.2+, 21.5+ months min,
Slide 18: IMA203 Summary of Clinical Data and Planned Next Steps
ACTengine® IMA203 TCR - T Monotherapy Targeting PRAME in Melanoma Summary of Clinical Data and Planned Next Steps Next Steps Ongoing alignment with FDA on trial design of the randomized Phase 2/3 trial in 2L+ melanoma to start in 2024 S a f e ty Anti - Tumor Activity Durability R P 2 D Broad Reach F
Slide 19: High Unmet Medical Need in Cutaneous and Uveal Melanoma
High Unmet Medical Need in Cutaneous and Uveal Melanoma Clinically and Commercially Attractive Features of IMA203 Uveal Melanoma Cutaneous Melanoma Kimmtrak - refractory, CPI/chemotherapy - refractory 2L+ CPI - refractory, BRAF/MEK inhibitor - refractory if BRAF mutation+ 2L+ Patient P o pu l a ti o
Slide 20: IMA203CD8 GEN2 – Leveraging CD8 and CD4 cells
IMA203CD8 GEN2 – IMA203 TCR - T Monotherapy Leveraging CD8 and CD4 cells Differentiated Pharmacology Compared to 1 st - Generation TCR - only Approaches • IMA203CD8 (GEN2) designed to broaden the clinical potential of IMA203 TCR - T monotherapy by adding functional CD4 T cells via co - transduction
Slide 21: IMA203CD8 (GEN2) – Preclinical Assessment of Anti-Tumor Efficacy
IMA203CD8 (GEN2) – Preclinical Assessment of Anti - Tumor Efficacy Functional CD4 T cells Mediate Longer Anti - Tumor Activity than CD8 T cells in vitro 21 0 .0 0 .5 1 .0 1 .5 2 .0 CD8 0 50 100 150 200 250 300 350 400 450 Hours after Coculture Tumor fold growth 0 .0 0 .5 1.0 1 .5 2 .0 CD4 0 50 100 1
Slide 22: IMA203CD8 (GEN2) – Overview of Patient Characteristics
* Patients with at least one available tumor response assessment post infusion; IMA203CD8 DL3: 0.2 - 0.48x10 9 TCR - T cells/m 2 BSA, IMA203CD8 DL4a: 0.481 - 0.8x10 9 TCR - T cells/m 2 BSA, All Comers N=12 Efficacy population* 3 (1, 5) Prior lines of systemic treatment (median, min, max) 50.0 LDH at
Slide 23: Tolerability Data – IMA203CD8 (GEN2)
Tolerability Data – IMA203CD8 (GEN2) % No. ( System organ class , preferred term) 100. 0 12 Patients with any adverse event 25. 0 3 Adverse events of special interest 25 .0 3 Cytokine release syndrome 1 0 .0 0 Immune effector cell - associated neurotoxicity syndrome 91. 7 11 Blood and lymphatic syst
Slide 24: IMA203CD8 (GEN2) – BOR and Response over Time
IMA203CD8 (GEN2) (N=12 # ) – BOR and Response over Time Data cut - off Sep 30, 2023 • 6 out of 7 responses ongoing • 11/12 patients show tumor shrinkage • Deepening of response from SD to PR in two patients (C - DL4a - 01, C - DL4a - 03) • Ongoing durable response 12+ months after infusion Not reach
Slide 25: IMA203CD8 (GEN2): Translational Data Shows Enhanced Pharmacology
IMA203CD8 (GEN2): Translational Data Shows Enhanced Pharmacology IMA203 Phase 1b vs IMA203CD8 (GEN2) Trend towards responses at lower cell dose and higher tumor burden with IMA203CD8 Higher peak expansion (C max ) of IMA203CD8 T cells when normalized to infused dose Higher activation levels in IMA20
Slide 26: Summary of IMA203CD8 Clinical Data and Planned Next Steps
ACTengine® IMA203CD8 (GEN2) TCR - T Monotherapy Targeting PRAME Summary of IMA203CD8 Clinical Data and Planned Next Steps • Enhanced primary and secondary pharmacology when compared to IMA203 • Manageable tolerability (2 DLTs at DL4b, dose escalation ongoing) • Initial clinical activity observed wit
Slide 27: Potential of IMA203 in Additional Solid Cancer Indications
PRAME mRNA expression in IMA203 Phase 1a and Phase 1b responders at RP2D (n=13) PRAME mRNA expression in IMA203CD8 (GEN2) responders (n=7) Potential of IMA203 in Additional Solid Cancer Indications % PRAME - positive patients 1 PRAME target expression distribution (blue histogram) based on TCGA RNAs
Slide 28: Leveraging the Full Breadth of PRAME in Three Steps
28 ACTengine® IMA203 / IMA203CD8 TCR - T Monotherapy Targeting PRAME Leveraging the Full Breath of PRAME in Three Steps Development Strategy Step 1 IMA203 in cutaneous melanoma (potentially bundled with uveal melanoma) as first tumor type targeted to enter registration - enabling trial Further dose
Slide 29: IMA203 TCR-T Has the Potential to Reach a Large Patient Population
Patient Population PRAME Positive R/R Incidence Incidence Selected Indications Based on R/R Incidence; PRAME and HLA - A*02:01+ 2,999 95% 7,700 99,800 Cut. Melanoma 298 91% 800 1,500 Uveal Melanoma 4,408 84% 12,800 19,900 Ovarian Carcinoma 4,255 97% 10,700 62,700 Uterine Carcinoma 779 100% 1,900 3,3
Slide 30: TCER — TCR Bispecifics
ooe immatics TCER® — TCR Bispecifics
Slide 31: TCER – Next-generation, Half-Life Extended Bispecifics
TCER® – Immatics’ Next - generation, Half - Life Extended Bispecifics Proprietary TCER® Format Consisting of Three Distinct Elements 31 High - affinity TCR domains targeting XPRESIDENT® - selected tumor - specific peptide - HLA molecules L o w - a ff i n i t y T cell recruiter against CD3/TCR Fc par
Slide 32: TCER – Next-generation, Half-Life Extended Bispecifics
TCER® – Immatics’ Next - generation, Half - Life Extended Bispecifics 32 pHLA targeting TCR x High - affinity (single digit nM) TCR targeting XPRESIDENT® - selected tumor - specific peptide - HLA molecules x Broad therapeutic window through XPRESIDENT® - guided affinity maturation (>1000x) 1 x Compl
Slide 33: Potency of Our Proprietary TCR Bispecific Format TCER
Potency of Our Proprietary TCR Bispecific Format TCER® 33 • Seven different TCR Bispecific formats were evaluated with a pHLA targeting TCR and the identical T cell recruiting antibody • TCER® format had higher combination of potency and specificity 2 than six alternative TCR Bispecific format desig
Slide 34: TCER Format Designed for Optimized Efficacy and Safety: Tumor Control
TCER® Format Is Designed for Optimized Efficacy and Safety Superior Tumor Control Using a Novel, Low - Affinity Recruiter 34 n = 6 mice/treatment group, n = 10 mice in vehicle group, 2 donors/group Dose : 0 . 025 mg/kg Proprietary, low - affinity T cell recruiting region demonstrates superior tumor
Slide 35: TCER Format: Reduced Recruiter-Mediated Cytokine Release
TCER® Format Is Designed for Optimized Efficacy and Safety Reduced Target - Unrelated Recruiter - Mediated Cytokine Release using a Low - Affinity Recruiter 35 T CE R ® Whole blood cytokine release assay N=3 HLA - A*02 - positive donors N=16 cytokines tested, 4 exemplary cytokines shown
Slide 36: Our TCER Portfolio
Our TCER® Portfolio Broad Pipeline of Next - Gen Half - Life Extended TCR Bispecifics 36 T CE R ® • PRAME peptide presented by HLA - A*02:01 • Start of clinical trial in Aug 2023, first clinical data expected 2H 2024 IM A 402 Potential for addressing different indications and large patient populatio
Slide 37: In Vivo Expressed TCER Molecules Targeting Cancer-specific pHLA Targets
In Vivo Expressed TCER® Molecules Targeting Cancer - specific pHLA Targets Combining Immatics’ Target and TCR Platforms with Moderna’s mRNA Technology 37 Moderna Delivery of TCER® biologics through mRNA Immatics Proprietary cancer targets & TCR Bispecifics format mRNA - encoded TCER® molecule XPRESI
Slide 38: TCER IMA401 Targeting MAGEA4/8
TCER® IMA401 Targeting MAGEA4/8 38
Slide 39: TCER IMA401 Targeting MAGEA4/8: Higher Target Density
TCER® IMA401 Targeting MAGEA4/8 Higher Target Density of MAGEA4/8 Peptide 39 MAGEA4 protein detection in tumor samples (IHC) 1 MAGEA4/8 target prevalences are based on TCGA and in - house data combined with a XPRESIDENT® - determined target individual MS - based mRNA expression threshold; qPCR - thr
Slide 40: TCER IMA401 (MAGEA4/8) – Anti-Tumor Activity in vitro
TCER® IMA401 (MAGEA4/8) – Assessment of Anti - Tumor Activity in vitro Patient - Derived Tumor Model 40 NSCLC adenocarcinoma: • Male, Caucasian, age 58, no therapy prior to surgery • Site of origin: lung, differentiation poor • Date of surgery: 1987, Freiburg Medical Center • Volume doubling time: 7
Slide 41: Trial Design – IMA401-101 Phase 1a Dose Escalation
41 180 µg 540 µg 1800 µg 2500 µg Key Eligibility Criteria O bje c ti v es P r i m a r y : • Determine MTD and/or RP2D Secondary: • Tolerability • Pharmacokinetics • Initial anti - tumor activity • Recurrent and/or refractory solid tumors • HLA - A*02:01 positive • MAGEA4/8 - positive as confirmed by
Slide 42: Baseline Characteristics
Baseline Characteristics Heavily Pre - treated Patients with a Broad Range of Tumor Types 42 1 Efficacy Analysis Set (EAS) prospectively defined in the study protocol: patients who received at least four IMA401 infusions and had at least one post - baseline efficacy assessment or clinical progressio
Slide 43: IMA401 Demonstrates Manageable Tolerability in N=35 Patients
43 IMA401 Demonstrates Manageable Tolerability in N=35 Patients Most Frequent Related AEs were Lymphopenia, CRS and Neutropenia ≥ Grade 3 All Grades TEAEs, n [%] 26 [74] 32 [91] Any 19 [54] 28 [80] Treatment - related ≥ Grade 3 All Grades Treatment - related AEs 1 , n [%] 11 [31] 12 [34] Lymphopenia
Slide 44: IMA401 Pharmacokinetics
IMA401 Pharmacokinetics TCER® Format Shows Extended Half - Life in Solid Cancer Patients 1 Half - lifes derived from 2nd PK profiles close to steady - state. Calculated by non - compartmental analysis (NCA) using Phoenix WinNonlin (Certara); Interquartile range (25% - 75% percentile): 13.5 - 22.2 da
Slide 45: Objective Responses are Associated with Target Expression
1 Patients in this analysis had received IMA401 infusions at ≥1 mg and showed MAGEA4/8 target expression above indicated MAGEA4/A8 high qPCR threshold (n=17); PD: Progressive disease; PR: Partial response; cPR: confirmed Partial response; SD: Stable disease. 45 Data cut - off Jul 23, 2024 Objective
Slide 46: IMA401 Demonstrates Anti-Tumor Activity
46 *Patients in this analysis are part of the efficacy analysis set with at least one post - treatment tumor assessment and had recei ved IMA401 infusions at ≥1 mg and showed MAGEA4/8 target expression higher than the MAGEA4/8 qPCR threshold (n=17); Confirmed ORR (cORR): Confirmed objective response
Slide 47: Clinical Activity in Heavily Pre-Treated Cancer Patients
Clinical Activity in Heavily Pre - Treated Cancer Patients 47 CT and MRI scans courtesy of treating physicians (Dr. Manik Chatterjee, University Hospital Wuerzburg and Dr. Max - Felix Häring, Eberhard Karls University Tue bingen); HNSCC: Head and neck squamous cell carcinoma; NET CUP: Neuroendocrine
Slide 48: TCER IMA402 Targeting PRAME
TCER® IMA402 Targeting PRAME 48
Slide 49: TCER IMA402 – Efficacy Assessment in vitro
TCER® IMA402 Targeting PRAME – Efficacy Assessment in vitro Tumor Cell Killing at Low Physiological PRAME Peptide Levels 49 140 120 100 80 60 40 20 0 10 - 1 10 0 10 1 10 2 10 3 10 4 10 5 IMA402 [pM] ~50 PRAME CpCs 0 140 120 100 80 60 40 20 0 10 - 1 10 0 10 1 10 2 10 3 10 4 10 5 IMA402 [pM] Cytotoxic
Slide 50: TCER IMA402 Achieves Durable Tumor Control of Large Tumors in vivo
TCER® IMA402 Achieves Durable Tumor Control of Large Tumors in vivo 50 - 2 9 0 50 0 100 0 150 0 200 0 250 0 0 1 0 2 0 3 0 4 0 5 0 6 0 7 0 Study day Median tumor volume [mm 3 ] Vehicle IMA402 [0.01 mg/kg] IMA402 [0.05 mg/kg] IMA402 [0.25 mg/kg] • Dose - dependent efficacy of IMA402 in cell line - der
Slide 51: Half-life Extended Format of IMA402 Confers Terminal Half-life of >1 Week
Half - life Extended Format of IMA402 Confers Terminal Half - life of >1 Week 51 pHLA – aFc Assay pHLA – aV L Assay • IMA402 shows a terminal serum half - life of ≈ 8 days in mice • IMA402 will be initially dosed weekly in the clinical trial • Dosing frequency may be adapted based on clinical data I
Slide 52: Phase 1/2 Clinical Trial to Evaluate TCER IMA402 Targeting PRAME
Phase 1/2 Clinical Trial to Evaluate TCER® IMA402 Targeting PRAME First Clinical Data Planned in 2H 2024 52 Phase 1: Dose Escalation Phase 2a: Dose Expansion Adaptive design aimed at accelerating dose escalation • Specific indications plus ongoing basket • Combination therapies • Optional dose/appli
Slide 53: Immatics' Proprietary Target and TCR Discovery Platforms
Immatics’ Proprietary Target and TCR Discovery Platforms 53
Slide 54: Our TCR-based Approaches Leverage the Full Target Space
Our TCR - based Approaches Leverage the Full Target Space beyond the Cancer Cell Surface 54 T e chn olo g y
Slide 55: True Cancer Targets & Matching Right TCRs
True Cancer Targets & Matching Right TCRs Goal to Maximize Anti - Tumor Activity and Minimize Safety Risks of TCR - based Immunotherapies 55 True Targets via XPRESIDENT® technology platform • are naturally presented on tumor tissues as identified by mass - spec • are absent or presented at only low
Slide 56: Pool of Prioritized Targets as Foundation for Future Value Generation
T e chn olo g y Pool of 200 Prioritized Targets as Foundation for Future Value Generation XPRESIDENT® Target Platform 56 200 Prioritized Targets Grouped in 3 Target Classes: 1. Well known and characterized parent protein (20%) e.g. MAGE family cancer testis antigens 2. Unknown or poorly characterize
Slide 57: Potential for Large Patient Populations across Multiple Solid Cancers
Potential for Large Patient Populations across Multiple Solid Cancers 57 Uterine Carcinoma – 97% Uterine Carcinosarcoma – 100% Sarcoma Subtypes – up to 100% Cut. Melanoma ≥ 95% Uveal Melanoma 1 ≥ 91% Ovarian Carcinoma – 84% Squamous NSCLC – 68% TNBC – 63% Small Cell Lung Cancer – 45% Kidney Carcinom
Slide 58: Identification of the most Relevant Target
Immatics’ Unique Capability – Identification of the most Relevant Target Example of MAGEA4/8 Peptide Target 58 1 Copy number per tumor cell (CpC) measured on a paired - sample basis by AbsQuant®, i.e. comparing MAGEA4 vs. MAGEA4/A8 peptide presentation on same sample, 2 Students paired T test p<0.00
Slide 59: Development of the Right TCR – XCEPTOR Technology
Development of the Right TCR – XCEPTOR® Technology TCR Discovery and Engineering for ACT and TCR Bispecifics 59 TCR Bispecifics T cell engaging receptor (TCER®) Adoptive Cell Therapy A C T e n g i n e® ACTallo® • Fast, efficient and highly sensitive discovery of highly specific, natural TCRs • Prote
Slide 60: Optimal Target Selection & TCR Specificity for Minimizing Safety Risks
Optimal Target Selection & TCR Specificity for Minimizing Safety Risks Unique Interplay between Technology Platforms Allows Early De - risking for Clinical Development 60 Target peptide presented on tumor cells Selective killing of tumor cells Target peptide presented on normal cells Of f - t a r ge
Slide 61: Bioinformatics and AI-Platform XCUBE
“AI Is Where the Data Is®” Bioinformatics and AI - Platform XCUBE 61 Data Engineering Development of data warehouses & user interfaces Data Science Development of statistical & machine learning models Data Processing Processing of mass - spec & next - gen sequencing data 1 THERAPEUT I C KNOWLEDGE XP
Slide 62: Immatics' Robust Intellectual Property Portfolio
Immatics’ Robust Intellectual Property Portfolio Protection Strategy of Key Assets in Major Markets and Beyond 62 T echnolo g i e s T a r g e t s T CRs T C E R® The r ap e u t ic Uses Cell Therapy TCRs with high affinity and specificity profile Differentiated technologies, platforms and assays for T
Slide 63: ACTengine IMA204 – TCR-T Targeting COL6A3 Exon 6
ACTengine® IMA204 – TCR - T Targeting COL6A3 Exon 6 63
Slide 64: ACTengine IMA204 First-in-Class TCR-T Targeting Tumor Stroma
ACTengine® IMA204 First - in - Class TCR - T Targeting Tumor Stroma Key Features 64 HLA - A*02 - presented peptide derived from COL6A3 exon 6 Naturally and specifically presented on tumors at high target density 1 : 100 - 700 copies/cell Novel tumor stroma target identified and validated by XPRESIDE
Slide 65: ACTengine IMA204 – High Affinity, CD8-independent TCR
ACTengine® IMA204 – High Affinity, CD8 - independent TCR Complete Tumor Eradication in vitro & in vivo 1 by Affinity - enhanced IMA204 TCR CD8 - independent TCR leads to tumor eradication in all mice treated 65 W Si Do ild t ngl ub l ype e e m muta n u t a n t t T u N mo o n - t r c ra n ells o s du
Slide 66: ACTallo – Our Next-generation Off-the-shelf TCR-T
ACTallo® – Our Next - generation Off - the - shelf TCR - T 66
Slide 67: ACTallo – Immatics' Allogeneic Cell Therapy Approach
ACTallo® – Immatics’ Allogeneic Cell Therapy Approach • Off - the - shelf cell therapy , no need for personalized manufacturing reduced logistics and time to application • Potential for hundreds of doses from one single donor leukapheresis lower cost of goods • Use of healthy donor material prov
Slide 68: Why γδ T cells?
Why γδ T cells? γδ T cells Are Well Suited for an Off - the - shelf Cell Therapy Approach 68 γδ T cells x are abundant in the peripheral blood x show intrinsic anti - tumor activity x naturally infiltrate solid tumors & correlate with favorable prognosis x are HLA - independent, thus do not cause gr
Slide 69: Corporate Information & Milestones
Corporate Information & Milestones 69
Slide 70: Experienced Global Leadership Team
Harpreet Singh Chief Executive Officer Co - Founder >20 yrs biotech experience Arnd Christ Chief Financial Officer >20 yrs biotech experience (InflaRx, Medigene, NovImmune, Probiodrug) Carsten Reinhardt Chief Development Officer >20 yrs pharma & biotech experience (Micromet, Roche, Fresenius) Cedrik
Slide 71: Strong, Focused and Highly Integrated Trans-Atlantic Organization
Strong, Focused and Highly Integrated Trans - Atlantic Organization 71 Houston, Texas ~205 FTEs Cell therapy development & manufacturing Munich, Germany ~85 FTEs Various operating functions Tübingen, Germany ~255 FTEs Target & TCR discovery and TCR Bispecifics d ev e l o p me nt Corporate FTEs as of
Slide 72: Delivering the Power of T cells to Cancer Patients
Delivering th e P owe r of T ce lls to Ca n ce r P a t ie n t s © Immatics. Not for further reproduction or distribution. ww w .i mm a ti c s . c o m